{"link": "http://hdl.handle.net/10138/168814", "subject": "farmasia', 'farmasia", "wordcount": 24206, "major": "Natural Products as a Source for Rational Antichlamydial Lead-Discovery", "abstract": "Chlamydia pneumoniae (C. pneumoniae) and Chlamydia trachomatis (C. trachomatis) are among the most common infectious microbes in humans. C. pneumoniae represents approximately 10% of community-acquired pneumonias worldwide. Statistically, everyone becomes infected 2-3 times during their lifetimes. The persistent form of C. pneumoniae is associated with other chronic diseases, such as asthma and chronic obstructive pulmonary disease. C. trachomatis is a sexually transmitted pathogen, which may result in infertility and ectopic pregnancies. Of all the infective agents it is also the one to cause most cases of blindness. The chronic forms of Chlamydiae cannot be cured by antibiotics, and a vaccine against them does not exist. Acute forms can be treated with antibiotics; but, resistance is increasing, given that treatment of Chlamydiae relies on wide-spectrum antibiotics. In this thesis new biologically active extract and compounds from natural sources were found to inhibit the growth of C. pneumoniae and C. trachomatis, the antichlamydial activity against C. pneumoniae being higher with all of the studied compounds and an extract. The antichlamydial effect of six lignans from the berries of Schisandra chinensis (Turczaninov) Baillon and their possible role as lead -compounds in the early drug discovery process were investigated. An aqueous methanol extract from Schisandra chinensis berries and Schisandra lignans showed varying activity on two different clinical isolates of C. pneumoniae, CV-6 and K7. The Schisandra lignans were shown to act at the mid-cycle of the infection. In addition, it was found that the effect is more targeted to the intracellular forms of the bacteria than to the extra cellular forms. Moreover, the results suggest that the antichlamydial mechanism of these lignans is specific to the host cell Chlamydia interaction rather than caused by their antioxidative properties. Schisandra extract and lignans did not affect the growth of three common respiratory tract bacterial pathogens, nor did they inhibit the growth of seven common metabolically active species, suggesting a Chlamydia-selective action of the extract and the lignans. Most of the lignans did not decrease host cell viability at the studied concentrations. As effective and selective growth inhibitors of Chlamydia pneumoniae, non-toxic and most of them not violating the Lipinski s rule of five, these Schisandra lignans present excellent lead candidates for further drug discovery. Schisandra lignans were utilized in constructing a reference set for a novel ligand-based virtual screening process, which proved successful with a hit rate of 1.2%. Six non-toxic lead compounds were found, belonging to new antichlamydial chemotypes. A new chemical space for antichlamydial compounds was defined, for future antichlamydial drug discovery projects.', 'Chlamydia pneumoniae (C. pneumoniae) ja Chlamydia trachomatis (C. trachomatis) ovat yleisi\u00e4 ihmisen taudinaiheuttajia. C. pneumoniae aiheuttaa noin 10 % kaikista keuhkokuumetapauksista maailmanlaajuisesti, ja tilastollisesti kaikki saavat tartunnan jossain el\u00e4m\u00e4ns\u00e4 vaiheessa. C. pneumoniaen krooninen muoto on yhdistetty monien muiden kroonisten sairauksien patogeneesiin, kuten esimerkiksi astmaan ja keuhkoahtaumatautiin. C. trachomatis on sukupuolitauti, jonka on aiheuttaa hedelm\u00e4tt\u00f6myytt\u00e4 ja kohdunulkoisia raskauksia, sek\u00e4 valtaosan infektioper\u00e4isist\u00e4 sokeutumisista. Antibioottien teho klamydian kroonisiin muotoihin on puutteellinen, ja rokotetta ei ole saatavilla. Akuutti-infektiot voidaan hoitaa l\u00e4\u00e4kkeill\u00e4, mutta resistenssi n\u00e4it\u00e4 laajakirjoisia antibiootteja vastaan kasvaa koko ajan. T\u00e4ss\u00e4 ty\u00f6ss\u00e4 on tunnistettu uusi uute ja siit\u00e4 eristettyj\u00e4 yhdisteit\u00e4, jotka est\u00e4v\u00e4t C. pneumoniaen ja C. trachomatis  kantojen kasvua. Schisandra chinensiksen (Turczaninov) Baillon marjauutteen ja puhdasaineiden klamydian kasvua est\u00e4v\u00e4 vaikutus oli suurempi C. pneumoniaea, kuin C. trachomatista kohtaan. Kuuden marjoista eristetyn lignaanin osalta tutkittiin antiklamydia-aktiivisuutta ja soveltuvuutta johtomolekyyleiksi varhaisen vaiheen l\u00e4\u00e4kekehitykseen. Schisandra chinensiksen marjoista uutetulla vesi metanoli  uuteella ja eristetyill\u00e4 lignaaneilla todettiin vaihtelevaa aktiivisuutta kahden C. pneumoniaen kliinisen kannan, CV-6 ka K7, kasvun estossa. Havaittiin my\u00f6s, ett\u00e4 Schisandra lignaanien klamydian kasvua est\u00e4v\u00e4 vaikutus kohdistui infektiosyklin keskivaiheeseen, sek\u00e4 selv\u00e4sti enemm\u00e4n bakteerin solunsis\u00e4iseen kuin solunulkoiseen muotoon. Saatujen tulosten perusteella voidaan olettaa, ett\u00e4 n\u00e4iden lignaanien antiklamydiavaikutus kohdistuu erityisesti is\u00e4nt\u00e4solun ja klamydian v\u00e4liseen vuorovaikutukseen, ei niink\u00e4\u00e4n lignaanien antioksidatiivisiin ominaisuuksiin. Schisandra uute ja -lignaanit eiv\u00e4t vaikuttaneet muiden tutkittujen metabolisesti aktiivisten bakteerien kasvuun, mik\u00e4 viittaa n\u00e4iden yhdisteiden klamydiaselektiiviseen vaikutusmekanismiin. Suurin osa lignaaneista ei v\u00e4hent\u00e4nyt is\u00e4nt\u00e4solujen elinkykyisyytt\u00e4. N\u00e4m\u00e4 ei-toksiset, selektiiviset Chlamydia pneumoniaen kasvua est\u00e4v\u00e4t yhdisteet, jotka noudattavat Lipinskin viiden s\u00e4\u00e4nt\u00f6\u00e4 l\u00e4\u00e4kkeeksi sopivista yhdisteist\u00e4, ovat erinomaisia johtomolekyylej\u00e4 l\u00e4\u00e4kekehitykseen. Schisandra lignaaneja k\u00e4ytettiin referenssikokoelman muodostamiseen ligandiin perustuvaa virtuaaliseulontaa varten. T\u00e4m\u00e4 seulonta osoittautui menestykselliseksi l\u00f6ydettyjen osumamolekyylien m\u00e4\u00e4r\u00e4n ollessa 1,2 % seulotusta kirjastosta. T\u00e4ll\u00e4 menetelm\u00e4ll\u00e4 pystyttiin m\u00e4\u00e4ritt\u00e4m\u00e4\u00e4n kemiallisesta avaruudesta uusi antiklamydiaalinen alue, jota voidaan hy\u00f6dynt\u00e4\u00e4 tulevissa klamydian l\u00e4\u00e4kekehityksen projekteissa.", "faculty": "farmasia", "charcount": 144981, "commonwords": [["et", 275], ["al", 275], ["pneumoniae", 233], ["chlamydia", 198], ["compounds", 152], ["schisandrin", 147], ["lignans", 131], ["schisandra", 125], ["antichlamydial", 110], ["cell", 95], ["infection", 95], ["cells", 94], ["activity", 79], ["drug", 78], ["effect", 70], ["not", 70], ["growth", 70], ["against", 66], ["host", 57], ["chlamydial", 55]], "keywords": "", "unit": "farmasian tiedekunta', 'Helsingfors universitet, farmaceutiska fakulteten', 'University of Helsinki, Faculty of Pharmacy", "status": "doctor", "thesistype": "V\u00e4it\u00f6skirja (artikkeli)', 'Doctoral dissertation (article-based)', 'Doktorsavhandling (sammanl\u00e4ggning)', 'Text", "pagecount": 98, "title": "Natural Products as a Source for Rational Antichlamydial Lead-Discovery", "language": "en", "author": "Karhu, Elina", "date": "2016-12-09", "distinctwords": 4889}